Loading
GRAIL, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 10 Oct 2024.
GRAIL, Inc.: what insiders have been doing
Headquartered in Menlo Park, United States, GRAIL, Inc. belongs to the Healthcare & Pharma sector and traces its origins to 2015. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 56 filings.
Only sales appear on the open market, 33 sales in all totalling €97.9M, filed by 5 insiders. The largest single trade was a sale of €68.7M by Illumina, Inc., published on 18 November 2025.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 56 filings here. Our records for GRAIL, Inc. go back to 2024, with 1 purchase and 59 sales on the open market in total. The 10-K for the year ended 31 December 2025 shows 147.2 m USD of revenue and -408.4 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
119
Thresholds
n/a
Buy Volume
€93,226
1 ops. · all time
Sell Volume
€117M
59 ops. · all time
Who traded when
BuySaleJoshua J. Ofman28 sales
Aaron Freidin16 sales
Ragusa Robert P9 sales
Andrew John Partridge1 sale
Ding Chun R1 sale
Illumina, Inc.1 sale
Since the insiders bought
- +386.1%Entry US$14.49 · Close at T+365 US$70.44
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate GRAIL, Inc. Buy (bullish), based on 10 analysts. Average price target: US$131.30.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,283 of 24,148 companies
13.5
score / 100
Value20
Quality7
FCF yld-5.7%
Earn yld-7.8%
EV/EBITDA·
ROE-16%
Gross mgn-43%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$140.35
Analyst consensus
10 analystsBuy
US$74.00Target US$131.30(-6%)US$180.00
Income statement
RevenueUS$147.2M
Gross profit-US$62.6M-43% margin
EBITDA-US$377.8M-257% margin
Net income-US$408.4M-236.9% margin
Valuation
PER (forward)-17.0x
P/Book2.5x
Beta2.84
Balance sheet & cash
Market capUS$6.3B
Total debtUS$54.9M
Free Cash Flow-US$299.9M
Debt / Equity4%
Profitability & ownership
ROE-16.1%
ROA-12.0%
% insiders4.9%
% institutions86.3%
Last declaration on 16 October 2026
Declarations119 total
237 shares@ US$135.46Common StockSEC:0001628280-26-066150:0
153 shares@ US$135.46Common StockSEC:0001628280-26-066149:0
400 shares@ US$133.1175Common StockSEC:0001628280-26-066148:0
1,000 shares@ US$134.3843Common StockSEC:0001628280-26-066148:1
3,400 shares@ US$135.4435Common StockSEC:0001628280-26-066148:2
7,052 shares@ US$136.8329Common StockSEC:0001628280-26-066148:3
6,034 shares@ US$137.631Common StockSEC:0001628280-26-066148:4
2,114 shares@ US$138.7864Common StockSEC:0001628280-26-066148:5
148 shares@ US$135.46Common StockSEC:0001628280-26-066147:0
5,000 shares@ US$139.700.011% mcap9.8% of flowCommonSEC144:0001950047-26-010275
7,873 shares@ US$146.390.019% mcap100.0% of flowCommon StockSEC:0001628280-26-065365:0
23,619 shares@ US$146.390.056% mcap19.1% of flowCommon StockSEC:0001628280-26-065364:0
23,619 shares@ US$146.39060.054% mcap100.0% of flowCommon StockSEC144:0001628280-26-065138
7,873 shares@ US$146.39060.018% mcap92.0% of flowCommon StockSEC144:0001628280-26-065140
26,452 shares@ US$14.000.0076% mcap1.2% of flowCommon StockSEC:0001628280-26-063233:0
421 shares@ US$99.84990.0009% mcap0.1% of flowCommon StockSEC:0001628280-26-063233:6
1,779 shares@ US$92.26310.0034% mcap1.1% of flowCommon StockSEC:0001628280-26-063234:0
521 shares@ US$95.000.0010% mcap0.3% of flowCommon StockSEC:0001628280-26-063234:2
1,454 shares@ US$93.6060.0028% mcap0.4% of flowCommon StockSEC:0001628280-26-063233:2
1,400 shares@ US$97.84140.0028% mcap0.4% of flowCommon StockSEC:0001628280-26-063233:5
1,800 shares@ US$93.91560.0035% mcap1.1% of flowCommon StockSEC:0001628280-26-063234:1
2,125 shares@ US$92.31520.0040% mcap0.6% of flowCommon StockSEC:0001628280-26-063233:1
37,752 shares@ US$94.98280.073% mcap11.6% of flowCommon StockSEC:0001628280-26-063233:3
6,200 shares@ US$96.43080.012% mcap1.9% of flowCommon StockSEC:0001628280-26-063233:4
2,100 shares@ US$100.68050.0043% mcap0.7% of flowCommon StockSEC:0001628280-26-063233:7
25 of 119 declarations
About GRAIL, Inc.
GRAIL, Inc. (ticker: GRAL) is a U.S.-based healthcare company listed on the NASDAQ in the United States. It operates at the intersection of diagnostics, oncology, and preventative medicine, with a core mission to detect cancer early, when it can be cured. Its flagship commercial product is Galleri®, a multi-cancer early detection (MCED) blood test designed to identify cancer signals before symptoms appear. GRAIL’s technology platform also extends beyond a single product: the company uses next-generation sequencing, methylation-based analysis, machine learning, software, and automation to build a broader precision-oncology and early-detection franchise.
The company traces its roots to the scientific and commercial ecosystem around Illumina, and it became an independent public company after the spin-off of GRAIL from its former parent. GRAIL is headquartered in Menlo Park, California. From an investor’s standpoint, the company’s story is centered on a large unmet clinical need: broad-based cancer screening that can improve outcomes by shifting diagnosis earlier in the disease course. That makes GRAIL a high-potential but also highly execution-dependent healthcare name.
Read moreShow less
In competitive terms, GRAIL holds a distinctive position in an emerging category. Galleri is one of the best-known commercial MCED tests in the market, and its differentiation lies in its ability to screen for many of the deadliest cancers from a single blood draw. When a signal is detected, Galleri provides a cancer signal of origin to help guide downstream diagnostic work-up. This creates a potentially compelling value proposition for patients, providers, and health systems, although adoption still depends on clinical confidence, reimbursement, regulatory progress, and integration into care pathways.
GRAIL’s commercial footprint is primarily in the United States, while its scientific and regulatory profile is supported by international clinical programs, including the NHS-Galleri trial in England. Recent developments have been notable. On February 19, 2026, the company reported full-year 2025 results and said it sold more than 185,000 Galleri tests in 2025, with U.S. Galleri revenue up 26% year over year. GRAIL also completed its FDA PMA submission in January 2026, announced topline results from the NHS-Galleri trial, and completed analysis of the full PATHFINDER 2 study. In April 2026, it announced integration of Galleri into the Epic electronic health record platform, a potentially meaningful step toward broader health-system adoption. Overall, GRAIL remains a commercialization-and-evidence-building story with significant strategic optionality in a large addressable market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
